Business Description
Citius Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US17322U2078
Description
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 55.97 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 18.4 | |||||
| 3-Year EPS without NRI Growth Rate | 21.2 | |||||
| 3-Year FCF Growth Rate | 23.7 | |||||
| 3-Year Book Growth Rate | -1.9 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.08 | |||||
| 9-Day RSI | 30.19 | |||||
| 14-Day RSI | 31.22 | |||||
| 3-1 Month Momentum % | -23.53 | |||||
| 6-1 Month Momentum % | -33.34 | |||||
| 12-1 Month Momentum % | -51.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.75 | |||||
| Quick Ratio | 6.75 | |||||
| Cash Ratio | 4.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -41.9 | |||||
| Shareholder Yield % | 0.81 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -43.68 | |||||
| ROA % | -38.35 | |||||
| ROIC % | -55.85 | |||||
| 3-Year ROIIC % | -46.92 | |||||
| ROC (Joel Greenblatt) % | -1008.6 | |||||
| ROCE % | -43.35 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 26.1 | |||||
| PB Ratio | 0.28 | |||||
| Price-to-Tangible-Book | 1.4 | |||||
| EV-to-EBIT | -0.2 | |||||
| EV-to-Forward-EBIT | 1.55 | |||||
| EV-to-EBITDA | -0.2 | |||||
| EV-to-Forward-Revenue | 0.29 | |||||
| EV-to-FCF | -0.26 | |||||
| Price-to-Net-Current-Asset-Value | 1.33 | |||||
| Price-to-Net-Cash | 3.4 | |||||
| Earnings Yield (Greenblatt) % | -500 | |||||
| FCF Yield % | -115.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CTXR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Citius Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -6 | ||
| Beta | 1.01 | ||
| 3-Year Sharpe Ratio | -0.48 | ||
| 3-Year Sortino Ratio | -0.68 | ||
| Volatility % | 105.6 | ||
| 14-Day RSI | 31.22 | ||
| 14-Day ATR ($) | 0.918309 | ||
| 20-Day SMA ($) | 4.78075 | ||
| 12-1 Month Momentum % | -51.84 | ||
| 52-Week Range ($) | 2.55 - 26.75 | ||
| Shares Outstanding (Mil) | 7.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Citius Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Citius Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Citius Pharmaceuticals Inc Frequently Asked Questions
What is Citius Pharmaceuticals Inc(CTXR)'s stock price today?
The current price of CTXR is $3.06. The 52 week high of CTXR is $26.75 and 52 week low is $2.55.
When is next earnings date of Citius Pharmaceuticals Inc(CTXR)?
The next earnings date of Citius Pharmaceuticals Inc(CTXR) is 2025-02-14 Est..
Does Citius Pharmaceuticals Inc(CTXR) pay dividends? If so, how much?
Citius Pharmaceuticals Inc(CTXR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers